{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:55Z","timestamp":1790398795229,"version":"4.1.0"},"reference-count":21,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5582\/ddt.2026.01068","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:10:55Z","timestamp":1790287855000},"source":"Crossref","is-referenced-by-count":0,"title":["The conversion window in hepatocellular carcinoma: When resectability alone is not an indication for surgery"],"prefix":"10.5582","author":[{"given":"Weiping","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China."},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China."},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[{"name":"National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Finn RS, Qin S, Ikeda M, <i>et al<\/i>. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382:1894-1905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Abou-Alfa GK, Lau G, Kudo M, <i>et al<\/i>. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022; 1:EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yau T, Galle PR, Decaens T, <i>et al<\/i>. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial. Lancet. 2025; 405:1851-1864.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kokudo N, Kokudo T, Song P, Tang W. Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma. Glob Health Med. 2024; 6:170-173.","DOI":"10.35772\/ghm.2024.01002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hakoda H, Ichida A, Hasegawa K. Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma. Biosci Trends. 2024; 18:525-534.","DOI":"10.5582\/bst.2024.01372"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Akahoshi K, Shindoh J, Tanabe M, <i>et al.<\/i> Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023. Liver Cancer. 2024; 13:579-589.","DOI":"10.1159\/000538627"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Ichida A, Tateishi R, Hatano E, Taketomi A, Tanabe M, Nouso K, Minami Y, Murakami T, Shimada M, Hasegawa K. Definition of conversion therapy and neoadjuvant therapy for hepatocellular carcinoma: A consensus guideline from the Japan Liver Cancer Association. Liver Cancer. 2026; doi:10.1159\/000552928.","DOI":"10.1159\/000552928"},{"key":"8","unstructured":"8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025; 82:315-374."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Reig M, Sanduzzi-Zamparelli M, Forner A, <i>et al.<\/i> BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. 2026; 84:631-654.","DOI":"10.1016\/j.jhep.2025.10.020"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Xu H, Zhang H, Li B, Chen K, Wei Y. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: A systematic review and meta-analysis. BMC Cancer. 2024; 24:1008.","DOI":"10.1186\/s12885-024-12772-y"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Deng M, Zhong C, Li D, Guan R, Lee C, Chen H, Qin W, Cai H, Guo R, Chen Z. Hepatic arterial infusion chemotherapy-based conversion hepatectomy in responders versus nonresponders with hepatocellular carcinoma: A multicenter cohort study. Int J Surg. 2025; 111:135-145.","DOI":"10.1097\/JS9.0000000000002043"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Zhao W, Zhang X, Zhong A, Jiang C, Cui R, Yu X, Lin S. Conversion hepatectomy and survival in initially unresectable hepatocellular carcinoma: A systematic review and meta-analysis with quantitative bias analysis. World J Surg Oncol. 2026; doi:10.1186\/s12957-026-04498-x.","DOI":"10.1186\/s12957-026-04498-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sun HC, Zhu XD, Shen F, <i>et al<\/i>. Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): A multicentre, open-label, randomised, phase 3 trial. Lancet. 2026; 408:699-710.","DOI":"10.1016\/S0140-6736(26)01252-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cheng Y, Xie K. When resectability emerges after systemic therapy in hepatocellular carcinoma: A proposed response-guided consolidation framework. J Hepatocell Carcinoma. 2026; 13:613934.","DOI":"10.2147\/JHC.S613934"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wang Z, Sun H, Zhou J, <i>et al<\/i>. Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition). Hepatobiliary Surg Nutr. 2026; 15:72.","DOI":"10.21037\/hbsn-2025-129"},{"key":"16","unstructured":"16. Genentech, Inc. Avastin (bevacizumab) prescribing information. <i>https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf<\/i> (accessed September 9, 2026)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li S, Li M, Zhu F, Qin Y, Tang W, Yao J, Chen J, Liu L, Liang Z, Wei H, He Y, Wang G, Zhang J, Xiang B. Optimal timing of surgery after conversion therapy for initially unresectable hepatocellular carcinoma: A multicenter study integrating major pathological response and treatment duration. Front Immunol. 2026; 17:1911781.","DOI":"10.3389\/fimmu.2026.1911781"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zeng ZX, Wu JY, Wu JY, Zhang ZB, Wang K, Zhuang SW, Li B, Zhou JY, Lin ZT, Li SQ, Li YN, Fu YK, Yan ML. Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery. Liver Cancer. 2024; 13:498-508.","DOI":"10.1159\/000536376"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Scheiner B, Kang B, Balcar L, <i>et al<\/i>. Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy. Hepatology. 2025; 81:1714-1727.","DOI":"10.1097\/HEP.0000000000001163"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Aoki T, Kudo M, Nishida N, <i>et al<\/i>. Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: A multicenter proof-of-concept study. J Gastroenterol. 2025; 60:738-753.","DOI":"10.1007\/s00535-025-02233-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016; 183:758-764.","DOI":"10.1093\/aje\/kwv254"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/advpub\/0\/advpub_2026.01068\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:29:58Z","timestamp":1790396998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/advpub\/0\/advpub_2026.01068\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01068","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026.01068"}}